obesity

Oct 26, 2026

Summary GLP-1 therapies are evolving beyond diabetes and obesity management into a multi-indication cardiometabolic drug platform, with expanding applications across cardiovascular disease, chronic kidney disease (CKD), metabolic dysfunction-associated steatohepatitis (MASH), and obstructive sleep apnea (OSA). ...

Oct 21, 2026

Two people sit down to the same bowl of oatmeal. One feels steady and energized for hours. The other crashes by mid-morning, hungry and foggy. For decades, nutrition science treated both as the same "average eater" and handed them the same advice: eat more whole grains, cut saturated fat, watch your sugar. Yet anyo...

Oct 13, 2026

Efzimfotase Alfa Shows Numerical Improvement in Six-Minute Walk Distance Versus Placebo in HICKORY Phase III Trial Results from the HICKORY Phase III trial indicated that efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy, did not achieve statistical significance for the primary endpoint ...

Sep 22, 2026

Novo’s CagriSema Demonstrates Superior Weight Loss Over Tirzepatide in REIMAGINE 5 Novo Nordisk announced topline results from the Phase 3 REIMAGINE 5 and REDEFINE 9 trials evaluating once-weekly CagriSema (cagrilintide and semaglutide), an investigational therapy and the company’s next-generation approach to we...

Sep 21, 2026

Summary Semaglutide patent expiry is staggered, not simultaneous: early wave in 2026 (India, China, Brazil, Canada, South Africa), mid wave ~2031 (UK, EU4, Japan), late wave 2032–33 (US). India and China are the biggest near-term battlegrounds, covering ~40% of the world population and a third of global obes...

Sep 08, 2026

Novo Nordisk’s STEP Young Phase 3 Study Shows Semaglutide Reduced Obesity Classification in 40.4% of Children Novo Nordisk announced the initial results from the STEP Young Phase 3 trial, which evaluated once-weekly semaglutide in combination with lifestyle modifications, including a reduced-calorie diet and inc...

Jul 10, 2026

Summary The obesity treatment market has shifted from a niche category to a major pharma growth engine, with revenues in the leading markets rising from about $16 billion in 2025 to a projected $80 billion by 2034 and potentially more than $100 billion by 2036. Eli Lilly led the category in 2025, driven by M...

Jun 15, 2026

Summary The obesity drug landscape is shifting from injectable GLP-1s to oral pill-based treatments, marking a major turning point in pharmacotherapy. Two oral GLP-1s have now received FDA approval: Novo Nordisk's WEGOVY pill (December 2025) and Eli Lilly's FOUNDAYO (April 2026). Several companies, such a...

Jan 23, 2026

The 44th Annual J.P. Morgan Healthcare Conference, held January 12-15, 2026, in San Francisco, revealed a pharmaceutical sector at an inflection point. With major blockbusters facing patent expirations, industry leaders such as Eli Lilly, Novo Nordisk, Bristol Myers Squibb, AbbVie, Bayer, Pfizer, Novartis, Roche, M...

Dec 30, 2025

Novo Nordisk Secures US Approval for WEGOVY Novo Nordisk has achieved a significant regulatory milestone with the U.S. FDA approval of WEGOVY (semaglutide) for the treatment of obesity in pediatric patients aged 12 years and older. While WEGOVY has already revolutionized the adult weight management market, this ...